Three things to know:
- Lemonaid Health is expected to be acquired for $400 million, with 25 percent paid in cash and 75 percent paid in 23andMe stock.
- The genomics company plans to expand into telemedicine and prescription drug delivery, according to the report. Anne Wojcicki, CEO of 23andMe, said the company will combine providing personal genetic profiles with giving patients and healthcare providers more data on health risks and treatments, Market Watch reported.
- The deal is expected to close by the end of the year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.